NCT04440280View on ClinicalTrials.gov

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

April 29, 2026

Study Completion Date

April 30, 2027

Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
DRUG

N-acetyl cysteine (NAC) 10% solution

N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.

DRUG

N-acetyl cysteine (NAC) 20% solution

N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.

DRUG

Visine Dry Eye Relief eye drops

Visine Tears Dry Eye Relief artificial tears ophthalmic solution

Trial Locations (1)

02114

RECRUITING

Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors
lead

Massachusetts Eye and Ear Infirmary

OTHER